Insights
Newsletters
All Eyes on AI: Regulatory, Litigation, and Transactional Developments – Q1 2026
Wilson Sonsini is pleased to present the next edition of All Eyes on AI: Regulatory, Litigation, and Transactional Developments, which closely follows the evolving regulatory landscape for artificial intelligence (AI) in the U.S., new EU regulations for AI, international developments, litigation, recent deal highlights, firm publications, and other AI and machine learning highlights.
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Newsletters
The Entrepreneurs Report – Q1 2026
Wilson Sonsini is pleased to present the Q1 2026 edition of The Entrepreneurs Report. We’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the first quarter, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general.
All Results
Alerts
7.10.26
The FTC After Slaughter: What Businesses Need to Understand
On June 29, 2026, the U.S. Supreme Court issued its opinion in Trump v. Slaughter, where the six-Justice majority held that appointed agency officials who wield executive power are subject to presidential removal. In so holding, the Court overruled its 1935 decision in Humphrey’s Executor v. United States, 295 U.S. 602 (1935), which for nearly a century stood for the principle that Congress can create independent agencies whose leaders can only be removed for cause.
Client Highlights
7.09.26
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Client Highlights
7.09.26
Wilson Sonsini Advises Standard Bots on $200 Million Series C
On June 11, 2026, Standard Bots, the largest manufacturer of AI-native, industrial robotics in the United States, announced a $200 million Series C led by RoboStrategy and existing investors, valuing the company at $1 billion. Standard Bots is also expanding its manufacturing footprint in New York, increasing its ability to design, assemble, and deploy American-made robots at scale. Wilson Sonsini Goodrich & Rosati advised Standard Bots on the transaction.
Alerts
7.08.26
SCOTUS Ruling Calls into Question EU-U.S. Personal Data Flows
On June 29, 2026, the Supreme Court of the U.S. (SCOTUS) held in Trump v. Slaughter that the U.S. President can dismiss members of the Federal Trade Commission (FTC) at will, rather than only for cause, overruling existing precedent regarding independent agencies. This decision of domestic constitutional law could also change the rules governing transfer of personal data from the European Economic Area (EEA, which includes the 27 European Union countries plus Iceland, Liechtenstein, and Norway) to the U.S.
Client Highlights
7.08.26
Wilson Sonsini Advises Arca on $64 Million Series A
On June 24, 2026, Arca Wealth (Arca), an AI-native wealth management company that brings personalized, advisor-led financial services, exited stealth and announced it secured $64 million across its seed round and Series A. The $48.5 million Series A was led by General Catalyst, with strong backing from Index Ventures and Venrock. Venrock also led the company's $15.5 million seed round. Wilson Sonsini Goodrich & Rosati advised Arca on the transaction.
Client Highlights
7.08.26
Wilson Sonsini Advises Crinetics on Patent Matters Related to $10 Billion Acquisition by Vertex
On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases, announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Wilson Sonsini Goodrich & Rosati is patent counsel to Crinetics and advised the company on patent matters related to the transaction.
Client Highlights
7.08.26
Wilson Sonsini Advises Insilico on Collaboration with Takeda
On July 1, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence and automation, announced a strategic collaboration agreement with Takeda to use Insilico’s proprietary end-to-end platform, Pharma.AI, to advance drug candidates across various therapeutic areas, with a potential initial value of $600 million. Insilico will lead drug discovery, while Takeda will further development, including advancing candidates past clinical trials.
Client Highlights
7.08.26
Wilson Sonsini Advises Monogram on $40 Million Seed Round as Company Emerges from Stealth
On July 7, 2026, Monogram, a developer of an artificial intelligence (AI) application built around visual interface, emerged from stealth and announced a $40 million seed round led by DST Global and Lux Capital. Wilson Sonsini Goodrich & Rosati advised Monogram on the transaction.
Client Highlights
7.08.26
Wilson Sonsini Advises TwelveLabs on $100 Million Series B
On July 1, 2026, TwelveLabs, a leading video intelligence company, announced it has raised $100 million in Series B funding. The round was co-led by NEA and NAVER Ventures with participation from Amazon, Radical Ventures, Korea Investment Partners, Index Ventures, Quadrille Capital, and Red Bull Ventures. Wilson Sonsini Goodrich & Rosati advised TwelveLabs on the transaction.
Podcasts
7.07.26
NextGen VC Podcast – Why the Future of Biotech Starts with the Brain
What does neuroscience have to do with venture capital? Quite a bit, according to Jason Pitts, Ph.D., principal at General Atlantic. In the latest episode of the NextGen VC Podcast, hosts and Wilson Sonsini partners Mike Hostetler and Jen Fang sit down with Jason to talk about the winding path that took him from studying the brain at Cornell University to evaluating some of the most promising companies in biotech.
Client Highlights
7.07.26
Wilson Sonsini Advises Vicus Ventures on Fund I Launch
On June 30, 2026, Vicus Ventures closed Fund I, a $55 million debut seed fund, with a strategic group of 55 limited partners including General Catalyst, Bain Capital, and Kleiner Perkins. Wilson Sonsini Goodrich & Rosati served as counsel to Vicus Ventures in connection with the launch.
Blog Posts
7.06.26
Updated SEC Rulemaking Agenda Published
On July 3, 2026, the Office of Information and Regulatory Affairs released its 2026 Regulatory Plan. Included in the release is a Statement of Regulatory Priorities for Fiscal Year 2026 from the SEC, along with a table of the SEC’s anticipated rulemaking activity through Fall 2026.